ScreenerHero

COLL Collegium Pharmaceutical, Inc. - Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · collegiumpharma.com
21.99USD-0.14%Mkt Cap: 682.60M $P/E: 17.34

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap682.60M USD
Enterprise Value1.81B USD
Revenue (TTM)808.21M USD
Gross Profit463.26M USD
Net Income (TTM)62.87M USD
Revenue/Share25.30 USD
Last Price21.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees423
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)17.34
P/E (Forward)3.29
PEG0.65
EV/EBITDA4.46
EV/Revenue2.23
P/S0.89
P/B2.29
EPS (TTM)1.27
EPS (Forward)6.68
52W Range
21.432% of range50.79
52W High50.79 USD
52W Low21.43 USD
Profitability
Gross Margin59.35%
Oper. Margin5.65%
EBITDA Margin50.14%
Profit Margin8.05%
ROE20.84%
ROA3.79%
Growth
Revenue Growth6.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF329.32M USD
CapEx (TTM)1.74M USD
FCF Margin40.09%
FCF Yield47.47%
Net Debt1.09B USD
Net Debt/EBITDA2.69
Balance Sheet
Debt/Equity2.70
Current Ratio1.03
Quick Ratio0.70
Book Value/Sh9.60 USD
Cash/Share3.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)49.00 USD
Upside (mean)+122.8%
Target Range43.00 USD – 60.00 USD
43.00+122.8% to mean60.00
# Analysts8
Ownership
Shares Out.32.56M
Float30.35M
Insiders1.15%
Institutions131.16%
Short Interest
Short Ratio6.7d
Short % Float20.82%
Short % Out.17.43%
Shares Short5.68M
Short (prev mo.)6.52M
Technical
SMA 5026.76 (-17.8%)
SMA 20035.75 (-38.5%)
Beta0.72
S&P 52W Chg14.58%
Avg Vol (30d)903.66K
Avg Vol (10d)798.41K
Technical Indicators
RSI (14)30.5
MACD-1.5995
MACD Signal-1.8708
MACD Hist.+0.2713
BB Upper24.09 USD
BB Middle22.77 USD
BB Lower21.45 USD
BB Width11.59%
ATR (14)1.063 USD
Vol Ratio (20d)0.74x